ERAS Stock Price, Erasca, Inc. Quote, Chart

Market Summary

USD1.98+0.13

Delayedas of 17 May 2024, 01:02 pm

7.03%

ERAS Stock Price

View Fullscreen

ERAS RSI Chart

ERAS Valuation

Market Cap

320.7M

Price/Earnings (Trailing)

-2.53

Price/Free Cashflow

-2.95

ERAS Price/Earnings (Trailing)

ERAS Profitability

Return on Equity

-43.99%

Return on Assets

-34.28%

Free Cashflow Yield

-33.9%

ERAS Fundamentals

ERAS Earnings

Earnings (TTM)

-126.9M

Earnings Growth (Yr)

-5.48%

Earnings Growth (Qtr)

-17.9%

Breaking Down ERAS Revenue

52 Week Range

1.823.38

(Low)(High)

Last 7 days

-6.1%

Last 30 days

-4.7%

Last 90 days

-8.5%

Trailing 12 Months

-36.1%

How does ERAS drawdown profile look like?

ERAS Financial Health

Current Ratio

10.14

ERAS Investor Care

Shares Dilution (1Y)

14.99%

Diluted EPS (TTM)

-0.84

Tracking the Latest Insider Buys and Sells of Erasca, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Dec 15, 2023	chacko david m.	acquired	11,886	1.5895	7,478	cfo and cbo
Dec 15, 2023	garner ebun	acquired	8,659	1.5895	5,448	general counsel & corp. sec.
Dec 06, 2023	start valerie denise harding	bought	18,480	1.848	10,000	-
Dec 06, 2023	lim jonathan e	bought	478,418	1.72	278,150	chairman & ceo
Dec 05, 2023	lim jonathan e	bought	1,217,760	1.687	721,850	chairman & ceo
Dec 04, 2023	casdin alexander w.	bought	49,785	1.6595	30,000	-
Oct 05, 2023	lim jonathan e	bought	2,026,000	2.026	1,000,000	chairman & ceo
Jun 08, 2023	lim jonathan e	bought	275,000	2.75	100,000	chairman & ceo
Apr 10, 2023	casdin alexander w.	bought	55,230	2.7615	20,000	-
Mar 28, 2023	lim jonathan e	bought	284,000	2.84	100,000	chairman & ceo

Which funds bought or sold ERAS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	BARCLAYS PLC	reduced	-51.89	-152,000	132,000	-%
May 15, 2024	QUADRANT CAPITAL GROUP LLC	sold off	-100	-6,373	-	-%
May 15, 2024	Squarepoint Ops LLC	reduced	-36.7	-73,074	115,354	-%
May 15, 2024	Prosight Management, LP	added	510	6,262,250	7,539,100	2.10%
May 15, 2024	Sio Capital Management, LLC	new	-	5,000,000	5,000,000	1.49%
May 15, 2024	TWO SIGMA ADVISERS, LP	added	65.35	799,509	2,133,950	-%
May 15, 2024	Cubist Systematic Strategies, LLC	reduced	-85.99	-136,757	21,438	-%
May 15, 2024	Tower Research Capital LLC (TRC)	reduced	-83.77	-32,571	6,067	-%
May 15, 2024	IPG Investment Advisors LLC	new	-	427,388	427,388	0.09%
May 15, 2024	ARMISTICE CAPITAL, LLC	reduced	-23.76	-4,530,160	12,714,300	0.17%

Are Funds Buying or Selling ERAS?

Are funds buying ERAS calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ERAS

No. of Funds

Unveiling Erasca, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	armistice capital, llc	5.36%	8,096,000	SC 13G
Feb 13, 2024	city hill, llc	8.5%	12,899,360	SC 13G/A
Jan 30, 2024	cormorant asset management, lp	0%	0	SC 13D/A
Mar 10, 2023	fmr llc	-	0	SC 13G/A
Feb 14, 2023	pfm health sciences, lp	3.2%	6	SC 13G/A
Feb 14, 2023	city hill, llc	9.7%	11,899,360	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Dec 21, 2022	cormorant asset management, lp	1.99%	2,986,402	SC 13D/A
Dec 19, 2022	novartis pharma ag	8.2%	12,307,692	SC 13G
Sep 06, 2022	pfm health sciences, lp	6.3%	6	SC 13G

Recent SEC filings of Erasca, Inc.

View All Filings

Date Filed	Form Type	Document
May 16, 2024	8-K	Current Report
May 15, 2024	144	Notice of Insider Sale Intent
May 09, 2024	S-3	S-3
May 09, 2024	S-8	Employee Benefits Plan
May 08, 2024	10-Q	Quarterly Report
May 08, 2024	8-K	Current Report
Apr 26, 2024	ARS	ARS
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	DEFA14A	DEFA14A
Apr 15, 2024	144	Notice of Insider Sale Intent

Peers (Alternatives to Erasca, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	27.86%	5.69%	-8.52	7.43	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.1B	2.0B	3.08%	-21.73%	-57.61	9.55	75.20%	68.82%
BMRN	14.6B	2.5B	-15.33%	-16.61%	71.11	5.91	13.74%	186.89%
INCY	12.8B	3.8B	6.86%	-11.90%	17.13	3.39	8.58%	129.81%
MID-CAP
BBIO	5.8B	107.9M	23.06%	120.60%	-10.63	48.09	54.84%	-28.31%
APLS	5.1B	524.1M	-18.99%	-52.96%	-12.22	9.73	394.93%	39.61%
AXSM	3.7B	251.0M	12.53%	-1.35%	-12.4	14.64	73.58%	-86.73%
ARWR	3.1B	240.7M	5.66%	-32.59%	-6.6	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-13.11%	-34.57%	-1.4K	3.01	56.43%	98.83%
SMALL-CAP
NVAX	2.0B	996.6M	260.65%	85.68%	-5.07	2.03	-26.66%	65.49%
CPRX	1.9B	411.3M	5.34%	30.65%	29.69	4.7	60.38%	-34.49%
CRBP	489.5M	881.7K	11.38%	343.80%	-14.5	481.06	-77.61%	33.36%
INO	330.9M	4.9M	32.47%	47.80%	-2.65	67.99	-54.97%	48.23%
IBIO	15.7M	2.1M	-6.67%	89.09%	-0.68	7.61	-13.45%	69.54%

Erasca, Inc. News

Latest updates

Erasca, Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet													(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4
Assets	-6.4%	370	395	419	441	468	515	446	445	475	501	522	210	125
Current Assets	-4.4%	307	321	306	324	398	444	366	381	403	420	492	197	120
Cash Equivalents	-17.6%	77.00	93.00	113	139	273	284	219	219	333	360	446	156	65.00
Net PPE	-4.3%	21.00	22.00	23.00	24.00	25.00	25.00	25.00	24.00	20.00	16.00	9.00	2.00	2.00
Liabilities	3.8%	82.00	79.00	80.00	78.00	81.00	103	81.00	50.00	51.00	45.00	39.00	20.00	17.00
Current Liabilities	15.6%	30.00	26.00	27.00	23.00	26.00	49.00	28.00	22.00	21.00	26.00	20.00	18.00	14.00
Shareholder's Equity	-8.9%	288	317	339	363	386	412	365	395	425	457	483	-	-
Retained Earnings	-5.8%	-641	-606	-576	-546	-514	-480	-345	-310	-274	-238	-207	-161	-115
Additional Paid-In Capital	0.8%	930	923	916	909	901	894	712	707	700	695	691	12.00	1.00
Shares Outstanding	0.3%	151	151	151	150	150	149	121	120	119	119	99.00	23.00	22.00
Float	-	-	-	-	297	-	-	-	432	-	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2
Cashflow From Operations	-34.1%	-33,251	-24,788	-24,120	-25,951	-26,358	-26,372	-23,945	-27,141	-25,806	-22,482	-23,219	-18,233	-15,666	-	-	-
Share Based Compensation	11.6%	6,848	6,136	6,238	7,012	6,845	5,380	5,232	5,055	4,442	2,883	3,017	1,636	795	-	-	-
Cashflow From Investing	119.4%	9,971	4,545	-1,812	-108,667	14,714	-4,867	-55,229	-9,191	-1,794	-63,949	-4,939	4,460	-162	-	-	-
Cashflow From Financing	1420.0%	6,931	456	7.00	649	183	96,196	427	992	460	1,107	317,573	180	120,537	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ERAS Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 28,574	$ 27,585
General and administrative	10,277	9,440
Total operating expenses	38,851	37,025
Loss from operations	(38,851)	(37,025)
Other income (expense)
Interest income	3,900	3,877
Other expense, net	(66)	(51)
Total other income (expense), net	3,834	3,826
Net loss	$ (35,017)	$ (33,199)
Net loss per share, basic	$ (0.23)	$ (0.22)
Net loss per share, diluted	$ (0.23)	$ (0.22)
Weighted-average shares of common stock used in computing net loss per share, basic	151,161,741	149,504,216
Weighted-average shares of common stock used in computing net loss per share, diluted	151,161,741	149,504,216
Other comprehensive income (loss):
Unrealized (loss) gain on marketable securities, net	$ (287)	$ 527
Comprehensive loss	$ (35,304)	$ (32,672)

ERAS Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 76,726,000	$ 93,075,000
Short-term marketable securities	220,959,000	219,275,000
Prepaid expenses and other current assets	8,938,000	8,326,000
Total current assets	306,623,000	320,676,000
Long-term marketable securities		9,642,000
Property and equipment, net	21,358,000	22,327,000
Operating lease assets	37,177,000	37,861,000
Restricted cash	408,000	408,000
Other assets	4,456,000	4,383,000
Total assets	370,022,000	395,297,000
Current liabilities:
Accounts payable	2,633,000	2,000,000
Accrued expenses and other current liabilities	16,577,000	20,186,000
Proceeds from prepayment of private placement	6,907,000
Operating lease liabilities	4,126,000	3,970,000
Total current liabilities	30,243,000	26,156,000
Operating lease liabilities, net of current portion	50,811,000	51,889,000
Other liabilities	559,000	566,000
Total liabilities	81,613,000	78,611,000
Commitments and contingencies (Note 11)
Stockholders' equity:
Preferred stock, $0.0001 par value; 80,000,000 shares authorized at March 31, 2024 and December 31, 2023; no shares issued and outstanding at March 31, 2024 and December 31, 2023
Common stock, $0.0001 par value; 800,000,000 shares authorized at March 31, 2024 and December 31, 2023; 151,497,138 and 151,462,103 shares issued at March 31, 2024 and December 31, 2023, respectively; 151,249,219 and 151,090,227 shares outstanding at March 31, 2024 and December 31, 2023, respectively	15,000	15,000
Additional paid-in capital	929,634,000	922,607,000
Accumulated other comprehensive (loss) income	(210,000)	77,000
Accumulated deficit	(641,030,000)	(606,013,000)
Total stockholders' equity	288,409,000	316,686,000
Total liabilities and stockholders' equity	$ 370,022,000	$ 395,297,000

About Erasca, Inc.

Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.

CEO	Dr. Jonathan E. Lim M.D.
WEBSITE	erasca.com
INDUSTRY	Biotechnology
EMPLOYEES	129

Erasca, Inc. Frequently Asked Questions

What is the ticker symbol for Erasca, Inc.? What does ERAS stand for in stocks?

ERAS is the stock ticker symbol of Erasca, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Erasca, Inc. (ERAS)?

As of Thu May 16 2024, market cap of Erasca, Inc. is 320.71 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ERAS stock?

You can check ERAS's fair value in chart for subscribers.

What is the fair value of ERAS stock?

You can check ERAS's fair value in chart for subscribers. The fair value of Erasca, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Erasca, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ERAS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Erasca, Inc. a good stock to buy?

The fair value guage provides a quick view whether ERAS is over valued or under valued. Whether Erasca, Inc. is cheap or expensive depends on the assumptions which impact Erasca, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ERAS.